Dr. Shaker Dahkil, MD
Claim this profileCancer Center of Kansas
Studies Cancer
Studies Breast Cancer
1 reported clinical trial
4 drugs studied
Area of expertise
1Cancer
PD-L1
AST
ALT
2Breast Cancer
PD-L1
AST
ALT
Affiliated Hospitals
More about Shaker Dahkil, MD
Clinical Trial Related4 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical TrialsTreatments Shaker Dahkil, MD has experience with
- Atezolizumab
- Bevacizumab
- IPI-549
- Nab-paclitaxel
Breakdown of trials Shaker Dahkil, MD has run
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Shaker Dahkil, MD specialize in?
Shaker Dahkil, MD focuses on Cancer and Breast Cancer. In particular, much of their work with Cancer has involved PD-L1 patients, or patients who are AST.
Is Shaker Dahkil, MD currently recruiting for clinical trials?
No, Shaker Dahkil, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Shaker Dahkil, MD has studied deeply?
Yes, Shaker Dahkil, MD has studied treatments such as Atezolizumab, Bevacizumab, IPI-549.
What is the best way to schedule an appointment with Shaker Dahkil, MD?
Apply for one of the trials that Shaker Dahkil, MD is conducting.
What is the office address of Shaker Dahkil, MD?
The office of Shaker Dahkil, MD is located at: Cancer Center of Kansas, Wichita, Kansas 67214 United States. This is the address for their practice at the Cancer Center of Kansas.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.